A new smartphone app joins a handful of digital therapeutics that have been cleared by the FDA. Whether apps that go through the FDA clearance process will ultimately reach patients remains unclear. Dror Ben-Zeev, PhD, is quoted.
Rejoyn: first app cleared by FDA for depression; cost, efficacy unclear
Psychiatric News | May 17, 2024